These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 761176)

  • 41. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer.
    Klefström P
    Cancer Treat Rep; 1980 Jan; 64(1):65-72. PubMed ID: 6991105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
    Elias L; Portlock CS; Rosenberg SA
    Cancer; 1978 Oct; 42(4):1705-10. PubMed ID: 361209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
    Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
    Cancer; 1977 Aug; 40(2):625-32. PubMed ID: 329975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.
    Krutchik AN; Buzdar AU; Blumenschein GR; Sinkovics JG
    Cancer Treat Rep; 1978 Oct; 62(10):1565-7. PubMed ID: 709557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Tada A; Ueno K; Yamazaki H; Nakamura T; Ito Y; Inagaki J
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):327-32. PubMed ID: 2494947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination chemotherapy with cyclophosphamide, adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer.
    Robert F; Omura G; Bartolucci AA
    Cancer; 1980 Jan; 45(1):1-5. PubMed ID: 6985825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.
    Anderson H; Thatcher N; Rankin E; Wagstaff J; Scarffe JH; Crowther D
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):49-52. PubMed ID: 6687868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer.
    Price LA; Hill BT; Marks P; Howell A; Monypenny I; Morrison JM
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):1-4. PubMed ID: 6682768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined cytotoxic and progestogen therapy for advanced breast cancer.
    Rubens RD; Begent RH; Knight RK; Sexton SA; Hayward JL
    Cancer; 1978 Oct; 42(4):1680-6. PubMed ID: 361207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
    Henderson IC; Gelman R; Canellos GP; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.